Mali leads Africa with innovative hybrid malaria vaccine approach

The Republic of Mali has made history by becoming the first nation worldwide to implement a hybrid malaria vaccine strategy. This groundbreaking initiative was launched on World Malaria Day, marking a significant milestone in the country’s public health efforts.

Under this pioneering approach, children aged 5 to 36 months will receive the first three vaccine doses on a monthly schedule throughout the year, based on age. Subsequent doses will be administered seasonally in May or June, just before the peak malaria transmission period. This strategic timing aligns with epidemiological data showing that malaria cases surge between July and December in Mali.

Mali’s malaria burden and vaccination response

Mali faces a substantial malaria challenge, accounting for 3.1% of global malaria cases (8.15 million) and 2.4% of global malaria deaths (14,328) in 2023. The country ranks among the 11 nations with the highest malaria burden globally. Between 2019 and 2023, Mali experienced a 1.4 million case increase, according to WHO data.

The hybrid vaccination strategy will initially target 19 priority districts across five regions: Kayes, Koulikoro, Mopti, Ségou, and Sikasso. The country has secured 927,800 doses of the R21/Matrix-M vaccine for this rollout.

Collaborative global health efforts

This historic vaccination drive is made possible through a collaboration between the Malian Ministry of Health and Social Development, Gavi, UNICEF, and the World Health Organization (WHO). The initiative builds upon previous successful vaccine trials in Ghana, Kenya, and Malawi, which demonstrated that malaria vaccines can reduce child mortality by 13% when administered to children under five.

The R21/Matrix-M vaccine, prequalified by WHO, targets Plasmodium falciparum, the deadliest malaria parasite in Africa. Clinical trials showed the vaccine reduces malaria cases by over 50% in the first year and extends protection with a fourth dose in the second year.

Key benefits of the hybrid approach

• Seasonal alignment: Doses administered before peak transmission periods maximize protection when children are most vulnerable
• Age-based administration: Initial doses follow a strict schedule based on age, while booster doses are timed seasonally
• Evidence-based: Supported by Malian research showing 75% reduction in malaria cases when administered seasonally

Regional context and future prospects

Mali’s initiative follows Uganda’s recent large-scale vaccine deployment and brings the total African countries using malaria vaccines to 20. These nations represent over 70% of the global malaria burden. By the end of 2025, an estimated 13 million additional African children are expected to be protected by malaria vaccines.

Gavi’s upcoming 2026-2030 strategy aims to help countries scale up vaccination programs, with a goal of protecting 50 million more children if sufficient funding becomes available.

Complementary malaria prevention measures

The vaccine initiative complements Mali’s existing malaria prevention strategies, including:

• Insecticide-treated bed nets
• Seasonal malaria chemoprevention
• Intermittent preventive treatment during pregnancy
• Indoor residual spraying

Expert perspectives on the breakthrough

Dr. Sania Nishtar, Gavi CEO: “We commend Mali’s commitment to saving lives and reducing malaria’s devastating impact. With 20 countries now deploying malaria vaccines and over 24 million doses delivered, consistent funding remains crucial to ensure this essential tool reaches those who need it most.”

Dr. Pierre Ngom, UNICEF Representative in Mali: “After 35 years of dedicated research and development, the malaria vaccine finally provides a powerful new tool to protect Malian children. While not a standalone solution, it represents a significant advance when combined with existing prevention methods.”

Dr. Patrick Kabore, WHO Representative in Mali: “The malaria vaccine represents one of the most important public health breakthroughs in recent times, providing critical protection for children against this deadly disease.”

Implementation challenges and solutions

Administering four or five vaccine doses requires systematic approaches to reach high-risk populations. Mali’s experience demonstrates how countries can adapt vaccination strategies to their specific epidemiological contexts:

• Nigeria’s phased rollout in high-burden states
• Chad’s triple vaccine deployment combining malaria, pneumonia, and diarrhea vaccines
• Integration of malaria vaccination in fragile health systems

The hybrid approach specifically addresses Mali’s seasonal transmission pattern, where over 50% of child malaria deaths occur during the July-December transmission season.

Vaccine safety and efficacy

The R21/Matrix-M and RTS,S/AS01 vaccines have been prequalified by WHO and demonstrated excellent safety profiles. Clinical trials in phase 3 showed:

• More than 50% reduction in malaria cases during the first year
• 75% protection when administered seasonally in high-transmission areas
• Sustained benefits with booster doses